Medical errors on the agenda at FDA/AHRQ (Agency for Healthcare Research and Quality) meeting
This article was originally published in Clinica
Executive Summary
The US FDA and the Agency for Healthcare Research and Quality are sponsoring a two-day public workshop on avoiding errors in transfusion medicine. Issues to be addressed on the first day of the workshop include: patient and medication identification; errors in manufacturing and testing of blood and blood components, system errors and cultural factors and the role of product deviation reporting in reducing transfusion errors. The second day will focus on current and future technology trends that should help prevent transfusion errors.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.